Literature DB >> 2345470

Saturation of intracellular cytosine arabinoside triphosphate accumulation in human leukemic blast cells.

G P Jamieson1, M B Snook, J S Wiley.   

Abstract

Accumulation of cytosine arabinoside triphosphate (araCTP) from a range of cytosine arabinoside (araC) concentrations (1-50 microM) was measured during incubations of leukemic cells freshly isolated from patients with acute leukemia. In all but one patient, increments in extracellular araC above 10 microM did not increase intracellular araCTP levels. This maximal level of araCTP accumulation ranged from 254 to 1607 pmol/10(7) cells attained after 1 h incubation and did not correlate with either the number of nucleoside transporters on the cell membrane or the Vmax of araC phosphorylation in cell free extracts. Extremely low araCTP accumulation (103 pmol/10(7) cells/h at 50 microM araC) was observed in an AML patient with the unusual finding of micromyeloblasts. These cells also had very low numbers of nucleoside transport sites (less than 500 sites/cell) and were mitotically inactive. The unique feature of the myeloblasts from this patient was that intracellular araCTP accumulation showed a linear dependence on extracellular araC up to 50 microM with no evidence of saturation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2345470     DOI: 10.1016/0145-2126(90)90035-8

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  2 in total

1.  Fludarabine-mediated circumvention of cytarabine resistance is associated with fludarabine triphosphate accumulation in cytarabine-resistant leukemic cells.

Authors:  Shuji Yamamoto; Takahiro Yamauchi; Yasukazu Kawai; Haruyuki Takemura; Shinji Kishi; Akira Yoshida; Yoshimasa Urasaki; Hiromichi Iwasaki; Takanori Ueda
Journal:  Int J Hematol       Date:  2007-02       Impact factor: 2.490

2.  AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicity.

Authors:  L H Lindner; H Ostermann; W Hiddemann; A Kiani; M Würfel; T Illmer; C Karsch; U Platzbecker; G Ehninger; E Schleyer
Journal:  Int J Hematol       Date:  2008-10-04       Impact factor: 2.490

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.